nafamostat has been researched along with Acute Lymphoid Leukemia in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murakawa, M | 1 |
| Okamura, T | 1 |
| Shibuya, T | 1 |
| Harada, M | 1 |
| Otsuka, T | 1 |
| Niho, Y | 1 |
1 other study available for nafamostat and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |